Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke

Neural Regeneration Research

Volumn 8, Issue 23, 2013, Pages 2144-2154

  Min, Lianqiu ^a   Shao, Shuai ^b   Wu, Xiaoning ^a   Cong, Lin ^c   Liu, Ping ^d   Zhao, Haiping ^d   Luo, Yumin ^d  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b Liaoyang Central Hospital   (China)

^c Department of Neurology Fuxin No 2 People's Hospital   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Brain injury; C reactive protein; D dimer; Fibrinogen; Grants supported paper; Inflammation; Ischemic stroke; Large artery atherosclerosis; Low density lipo protein cholesterol; Neural regeneration; Neuroregeneration; Thrombus; Triacylglycerol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTITHROMBOCYTIC AGENT;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASSISTED CIRCULATION; BLOOD CLOTTING; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; RANDOMIZED CONTROLLED TRIAL; THROMBOGENICITY; ADULT; ANTITHROMBOGENIC ACTIVITY; DRUG ACTIVITY;

EID: 84886648295     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.23.004     Document Type: Article

References (63)

1. Liu L, Wang D, Wong KS, et al. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011;42(12):3651-3654.
2. Jia Q, Liu LP, Wang YJ. Stroke in China. Clin Exp Phar-macol Physiol. 2010;37(2):259-264.
3. Gorelick PB, Wong KS, Bae HJ, et al. Large artery intra-cranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39(8):2396-2399.
4. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25 Suppl 1):IV6-19.
5. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythro-cyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry. 2011;82(9):986-992.
6. Rajeshwar K, Kaul S, Al-Hazzani A, et al. C-reactive pro-tein and nitric oxide levels in ischemic stroke and its sub-types: correlation with clinical outcome. Inflammation. 2012;35(3):978-984.
7. Kusche-Vihrog K, Urbanova K, Blanqué A, et al. C-reactive protein makes human endothelium stiff and tight. Hypertension. 2011;57(2):231-237.
8. Van Goor MP, Gomez-Garcia EB, Leebeek FW, et al. Thee148 C/T fibrinogen gene polymorphism and fibrino-gen levels in ischaemic stroke: a caseecontrol study. J Neurol Neurosurg Psychiatry. 2005;76(1):121-123.
9. Kofoed SC, Wittrup HH, Sillesen H, et al. Fibrinogen pre-dicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the co-penhagen city heart study. Eur Heart J. 2003;24(6):567-576.
10. Skoloudík D, Bar M, Sanák D, et al. D-dimers increase in acute ischemic stroke patients with the large artery occlu-sion, but do not depend on the time of artery recanaliza-tion. J Thromb Thrombolysis. 2010;29(4):477-482.
11. Hol J, Otterdal K, Breland UM, et al. Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One. 2012;7(7):e40673.
12. Esposito E, Rinaldi B, Mazzon E, et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α. J Neuroinflamma-tion. 2012;9:81.
13. Sellner J, Weber MS, Vollmar P, et al. The combination of interferon-Beta and HMG-CoA reductase inhibition in mul-tiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther. 2010;16(6):362-373.
14. Cheng G, Wei L, Zhi-Dan S, et al. Atorvastatin ameliorates cerebral vasospasm and early brain injury after sub-arachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci. 2009;10:7.
15. Berger C, Xia F, Maurer MH, et al. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev. 2007;58(1):48-56.
16. Tanaka N, Katayama Y, Katsumata T, et al. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res. 2007;1169:125-132.
17. Walter T, Szabo S, Suselbeck T, et al. Effect of atorvasta-tin on haemostasis, fibrinolysis and inflammation in nor-mocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, rando-mized, double-blind study. Clin Drug Investig. 2010;30(7):453-460.
18. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-contro-lled trial. Lancet. 2004;364(9435):685-696.
19. Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvasta-tin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost. 2002; 88(1):41-47.
20. Adams Jr HP, Bendixen BH, Kappelle LJ, et al. Classifica-tion of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35-41.
21. Mohr JP, Caplan LR, Melski JW, et al. Harvard Coopera-tive Stroke Registry: a prospective registry. Neurology. 1978;28(8):754-762.
22. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part I. J Lipid Res. 2004;45(9):1583-1593.
23. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercho-lesterolemia to coronary disease in humans. J Lipid Res. 2005;46(2):179-190.
24. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J Lipid Res. 2005;46(10):2037-2051.
25. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it-almost. J Lipid Res. 2006;47(1):1-14.
26. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006;47(7):1339-1351.
27. Kim OJ, Hong SH, Oh SH, et al. Association between VEGF polymorphisms and homocysteine levels in patients with ischemic stroke and silent brain infarction. Stroke. 2011;42(9):2393-2402.
28. Guiraud V, Amor MB, Mas JL, et al. Triggers of ischemic stroke: a systematic review. Stroke. 2010;41(11):2669-2677.
29. Wu T, Trevisan M, Genco RJ, et al. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study. Arch Intern Med. 2000;160(18):2749-2755.
30. Libby P, Aikawa M.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8(11):1257-1262.
31. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24-38.
32. Heart Protection Study Collaborative Group, Jonathan E, Derrick B, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377(9764):469-476.
33. Oh J, Teoh H, Leiter LA. Should C-reactive protein be a target of therapy? Diabetes Care. 2011;34 Suppl 2:S155-160.
34. Li L, Roumeliotis N, Sawamura T, et al. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004;95(9):877-883.
35. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smoothmuscle. Circulation. 2003;107(13):1783-1790.
36. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Athe-rosclerosis. 2008;201(2):318-325.
37. Ormstad H, Aass HC, Lund-Sørensen N, et al. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol. 2011; 258(4):677-685.
38. Terruzzi A, Valente L, Mariani R, et al. C-reactive protein and aetiological subtypes of cerebral infarction. Neurol Sci. 2008;29(4):245-249.
39. Ehling R, Pauli FD, Lackner P, et al. Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis. Fluids Barriers CNS. 2011;8:25.
40. Doolittle RF, Spraggon G, Everse SJ. Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol. 1998;8(6):792-798.
41. Haidaris PJ, Francis CW, Sporn LA, et al. Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. Blood. 1989;74(2):743-750.
42. Undas A, Brummel KE, Musial J, et al. Simvastatin de-presses blood clotting by inhibiting activation of proth-rombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248-2253.
43. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analyses and review of the literature. Ann Intern Med. 1993;118(12):956-963.
44. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investi-gators. Circulation. 1999;100(3):230-235.
45. Undas A, Brummel KE, Musial J, et al. Simvastatin de-presses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inacti-vation. Circulation. 2001;103(18):2248-2253.
46. Park YW, Koh EJ, Choi HY. Correlation between Serum D-Dimer Level and Volume in Acute Ischemic Stroke. J Korean Neurosurg Soc. 2011;50(2):89-94.
47. Barber M, Langhorne P, Rumley A, et al. Hemostatic func-tion and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004;35(6):1421-1425.
48. Biffi A, Devan WJ, Anderson CD, et al. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke. 2011;42(5):1314-1319.
49. Vidula H, Tian L, Liu K, et al. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Am J Cardiol. 2010;105(9):1348-1352.
50. Hol J, Otterdal K, Breland UM, et al. Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PLoS One. 2012;7(7):e40673.
51. Birnbaum Y, Lin Y, Ye Y, et al. Pretreatment with high dose statins, but not low dose statin, ezetimibe or the combina-tion of low dose statin and ezetimibe, limit infarct size in rats. J Cardiovasc Pharmacol Ther. 2008;13:72-79.
52. Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43(1):147-154.
53. Furie KL. High-dose statins should only be used in athe-rosclerotic strokes. Stroke. 2012;43(7):1994-1995.
54. Moonis M. High-dose statins should be used in all acute ischemic strokes. Stroke. 2012;43(7):1992-1993.
55. Sett AK, Robinson TG, Mistri AK. Current status of statin therapy for stroke prevention. Expert Rev Cardiovasc Ther. 2011;9(10):1305-1314.
56. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol. 1989;46(6):660-662.
57. Nedeltchev K, Der Maur TA, Georgiadis D et al. Ischaemic stroke in young adults: predictors of outcome and recur-rence. J Neurol Neurosurg Psychiatry. 2005;76(2):191-195.
58. Solomon A, Dobranici L, Kåreholt I, et al. Comorbidity and the rate of cognitive decline in patients with Alzheimer dementia. Int J Geriatr Psychiatry. 2011;26(12):1244-1251.
59. Ladenvall C, Jood K, Blomstrand C, et al. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke. 2006;37(8):2018-2023.
60. State Council of the People's Republic of China. Adminis-trative Regulations on Medical Institution. 1994.
61. Liu HM, Tu YK, Yip PK, et al. Evaluation of intracranial and extracranial carotid steno-occlusive diseases in Tai-wan Chinese patients with MR angiography: preliminary experience. Stroke. 1996;27(4):650-653.
62. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symp-tomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1991;325(7):445-453.
63. Wilkinson D, Doody R, Helme R, et al. Donepezil in vas-cular dementia: a randomised, placebo-controlled study. Neurology. 2003;61(4):479-486.